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Monoclonal antibodies have been successfully utilized as cancer-targeting therapeutics and
diagnostics, but the eﬃcacies of these treatments are limited in part by the size of the molecules
and non-speciﬁc uptake by the reticuloendothelial system. Peptides are much smaller
molecules that can speciﬁcally target cancer cells and as such may alleviate complications with
antibody therapy. Although many endogenous and exogenous peptides have been developed
into clinical therapeutics, only a subset of these consists of cancer-targeting peptides.
Combinatorial biological libraries such as bacteriophage-displayed peptide libraries are a
resource of potential ligands for various cancer-related molecular targets. Target-binding
peptides can be aﬃnity selected from complex mixtures of billions of displayed peptides on
phage and further enriched through the biopanning process. Various cancer-speciﬁc ligands
have been isolated by in vitro, in vivo, and ex vivo screening methods. As several peptides
derived from phage-displayed peptide library screenings have been developed into therapeutics
in current clinical trials, which validates peptide-targeting potential, the use of phage display
to identify cancer-targeting therapeutics should be further exploited.
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INTRODUCTION
Antibody engineering has provided many
advances in tumor-targeted therapeutics and diag-
nostics. As recombinant monoclonal antibodies
(mAbs) posses the general properties of high target
speciﬁcity and aﬃnity, they are well-suited therapeutic
agents and greater than 400 mAbs are currently in
clinical trials (Lin et al., 2005). Current Food and
Drug Administration approved antibody therapeutics
in clinical use include rituximab (anti-CD20 mAb
against Non-Hodgkin lymphoma, and B-cell lym-
phomas) and its related radioimmunoconjugates;
gemtuzumab ozogamicin (anti-CD33 mAb conju-
gated to a cytotoxic agent against acute myeloid leu-
kemia); alemtuzumab (anti-CD52 mAb against B-cell
chronic lymphocytic leukemia); cetuximab (anti-
epidermal growth factor receptor mAb against colo-
rectal cancer); trastuzumab (anti-HER2 mAb against
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nodeﬁciency virus; pIII, gene III protein; pVIII, gene VIII protein;
CK2, casein kinase 2; IL-6, interleukin-6; IL-6R, interleukin-6
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endothelial growth factor mAb against metastatic
colorectal cancer) (Adams and Weiner, 2005; Levene
et al., 2005). The successes of these therapeutic anti-
bodies validate the principle that cancer can be treated
through a cell surface targeted approach (Aina et al.,
2005).
Although antibody-based therapeutics have
increased the outlook for many cancer patients,
these therapies are of limited eﬃcacy especially
against solid malignancies (Stern and Herrmann,
2005) due in part to the size of the molecules
(approximately 160 kDa), elevated tumor interstitial
pressure, non-speciﬁc uptake into the reticuloendo-
thelial system, and immunogenicity (Jiang et al.,
2004; Aina et al., 2005). In addition, high aﬃnity
targeting antibodies experience a ‘binding site bar-
rier’ that limits tumor perfusion (Adams et al.,
2001). Engineering antibodies into Fab, and sin-
gle-chain Fv fragments (approximately 25 kDa),
and VHH domains or ‘nanobodies’ (approximately
15 kDa), has oﬀered improvements in tumor pene-
tration and in decreased immunogenicity (Cortez-
Retamozo et al., 2004).
Research indicates that pharmacokinetic prop-
erties are improved with the use of smaller ligands
(Reilly et al., 1995). As peptides are much smaller
molecules (1–2 kDa) than antibodies or antibody
fragments and demonstrate speciﬁcity and aﬃnity
for their targets, they may in part alleviate the
complications associated with antibody therapy
(Ladner et al., 2004). In general, peptides demon-
strate better tumor penetration, are subject to less
non-speciﬁc uptake, and should not elicit an immune
response. In addition, although therapeutic peptides
are vulnerable to proteolytic degradation, for
enhanced aﬃnity and stability, peptides can be
engineered with D-amino acids, cyclized, and blocked
at the N- and C-termini (Nilsson et al., 2000; Aina
et al., 2002).
Various endogenous peptides regulate bodily
functions such as peptide hormones, chemoattrac-
tants, neurotransmitters, cytotoxins, and antimicro-
bials. The discovery of endogenous peptides led to
the development of these peptides as targeting
therapeutics. For example, somatostatin, a naturally
occurring inhibitory peptide, was discovered to have
anti-neoplastic eﬀects on cells expressing somato-
statin receptors. A somatostatin analogue octreotide
has been utilized to treat a variety of tumors. It has
been conjugated to radiochemicals for diagnos-
tic imaging and to radionuclides for targeted
chemotherapeutic delivery (Liu, 2005). Recently
discovered bioactive endogenous peptides include
hepcidin, LEAP-2, b and h-defensins, various
ligands of orphan G-protein-coupled receptors, and
lympho-epithelial Kazal-type serine protease inhib-
iting peptides (Adermann et al., 2004). Although it
is estimated that greater than 850 endogenous
peptides exist, only a small subset of these consists of
cancer-associated peptides.
In addition to the clinical use of endogenous
peptides and their analogs, several exogenous
peptides have also been developed into clinical ther-
apeutics. Enfuvirtide, a 36-amino acid synthetic
peptide derived from human immunodeﬁciency virus
(HIV)-1 glycoprotein gp41, was the ﬁrst marketed
viral fusion inhibitor for the treatment of HIV
infection (Matthews et al., 2004). Ziconotide, a syn-
thetic equivalent of a naturally occurring 25-amino
acid peptide derived from the marine snail Conus
magnus, has been approved for treating acute and
chronic pain (Miljanich, 2004; Winquist et al., 2005).
Exenatide, a 39-amino acid peptide isolated from the
gila monster Heloderma suspectum, is an incretin
mimetic used to enhance glucose-dependent insulin
secretion in patients with type 2 diabetes mellitus
(Nielsen et al., 2004; Roges et al., 2005).
Phage-displayed random peptide libraries are a
valuable screening resource for identifying bioactive
peptides that interact with cancer targets (Mori,
2004). A typical library contains as many as 10
9
peptides, and often, multiple binding peptides can be
identiﬁed during peptide library screenings. Peptide
therapeutics developed through phage-display tech-
nology currently in clinical trials include: DX-88, an
inhibitor of plasma killikrein for the treatment of
hereditary angioedema (Ritchie, 2003); DX-890, an
inhibitor of human neutrophil elastase for treatment
of cystic ﬁbrosis (Wark, 2002); and Hematide, a
synthetic peptide-based erythropoiesis-stimulating
agent.* A number of papers have been published
describing the isolation of tumor and/or tumor vas-
culature-targeting peptides from phage-displayed
peptide libraries (Landon and Deutscher, 2003;
Zurita et al., 2003; Haubner and Wester, 2004;
Ruoslahti, 2004; Shadidi and Sioud, 2004; Kelly
et al., 2005; Su et al., 2005). This review attempts to
provide the reader an update on the status of cancer-
targeted peptides isolated from phage-displayed
peptide libraries.
* http://www.aﬀymax.com/pipeline_hematide.html
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Background
The ﬁeld of phage display began in 1985 when
George Smith reported that ﬁlamentous bacterio-
phage (phage) could be manipulated to display for-
eign amino acid sequences on the surface of the phage
particle as phage coat protein covalent fusions, while
maintaining the ability of phage infectivity for
propagation (Smith, 1985). Combinatorial phage-
displayed peptide libraries have since emerged as a
screening resource for identifying peptide ligands of
molecular targets. Cancer-speciﬁc ligands have been
isolated by in vitro, in vivo, and ex vivo library
screening methods. The reader is referred to a review
article covering identiﬁed peptidic ligands (Mori,
2004). The technology has also been applied in vari-
ous other applications, such as studying protein-
ligand interactions, aﬃnity maturation of previously
isolated binding peptides, mapping epitope binding
sites, and identifying enzyme substrate speciﬁcity
(Azzazy and Highsmith, 2002).
The utility of phage-displayed peptide library
technology derives from phage biology. Phage are
DNA-containing viruses that infect bacteria. Phage
can be genetically engineered to display polypeptides
on their surfaces that are encoded by the DNA
encapsulated in the viral particle. As such, phage
phenotype is physically linked to phage genotype.
Libraries are created with standard molecular clon-
ing techniques, which involve insertion of random-
ized oligonucleotide fragments in frame into the
phage coat protein genes. Phage displaying peptides
that interact with a molecular target can be aﬃnity
selected from complex mixtures of billions of dis-
played peptides, propagated by in vivo ampliﬁcation,
and subjected to additional rounds of aﬃnity selec-
tion, the process of which is referred to as ‘‘bio-
panning.’’
A typical round of biopanning includes (1) incu-
bating the peptide library with the target, (2) washing
away unbound phage, (3) eluting the remaining
bound phage, and (4) amplifying the eluted phage for
subsequent screening rounds (Fig. 1). After multiple
rounds of selection, enrichment of target-binding
phage is detected by phage titering and/or immuno-
logical assay methods. When suﬃcient enrichment
has occurred, individual phage are isolated and
sequenced to reveal any enriched binding motif. Each
step of the biopanning process can be optimized to
tailor to the unique characteristics of the target, and
the desired result of the screening project. For
instance, puriﬁed target proteins can be presented in
various formats, such as indirect immunoadhesion
formats, or captured through an aﬃnity tag (Mori,
2004). The criterion for target protein presentation in
a phage-displayed peptide library screening is that the
protein approximates its native conformation, as
evidenced by the retention of biological activity, such
as enzymatic activity or ability to participate in pro-
tein–protein interactions. Screening projects can also
be designed to select for high aﬃnity binding peptides
by increasing the stringency of phage binding,
washing, and/or elution steps and by imposing partial
structure of the displayed peptides by specifying
amino acid residues during library construction.
Typical dissociation constants of isolated peptides are
in the low to mid-micromolar range (Kay et al.,
2001).
Limits of Phage-Displayed Peptide Library
Technology
Two types of Escherichia coli bacteriophages
have been used in peptide phage-display systems,
ﬁlamentous phage (M13, f1, and fd) and lytic phage
(T7, T4, and k) (Castagnoli et al., 2001). Filamentous
phage particles are approximately 5 nm in diameter
and 1 lm in length and consist of major and minor
coat proteins and circular single-stranded DNA
(Fig. 2a). Peptides are typically displayed as N-
terminal gene III protein (pIII) fusions or gene VIII
protein (pVIII) fusions. pIII is a minor coat protein,
present in ﬁve copies at one tip of the phage particle.
Peptides fused to this protein are also expressed in
low copy numbers or monovalent display with the use
of a phagemid vector. pVIII is the M13 major coat
protein, of which thousands of copies encapsulate the
phage genome. Peptides fused to this protein can be
expressed in high copy number, which is sometimes
referred to as landscape phage display (Petrenko and
Smith, 2000), or low to mid-copy number using a
phagemid system. For the display of peptides as
fusions to each coat protein molecule present in the
phage particle, the randomized DNA is inserted
directly into the phage coat protein gene. Conversely,
for peptide displayed on only a few of the coat pro-
tein molecules, a phagemid vector supplying the
randomized DNA is utilized in conjunction with
helper phage infection (Russel et al., 2004). On the
other hand, bacteriophage T7 consists of an
approximately 60 nm diameter head encapsulating
linear double-stranded DNA, a tail, and six tail ﬁbers
(Fig. 2b). Peptides are displayed on the head surface
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protein 10. There are six T7 cloning vectors available
for use in the T7Select system (Novagen) that
accommodate amino acid lengths ranging from 50 to
1200, in peptide copy numbers of 0.1–1, 5–15, or 415*
depending on vector selection (Rosenberg et al.,
1996).
A critical aspect of peptide phage-display tech-
nology is the complexity of the library used during
screening, as successful isolation of peptides for a
target requires the presence of the peptide in the li-
brary chosen for biopanning. That is, the library
should be of suﬃcient diversity to contain potential
binding ligands for the target. Most phage-display
peptide library screenings have been conducted using
ﬁlamentous phage-displayed peptides (Szardenings,
2003), even though previous studies demonstrated
speciﬁc and positional amino acid biases in popula-
tions of peptides randomly selected from M13
libraries (Rodi et al., 2002). Although detailed phage
biology is beyond the scope of this review article, for
careful consideration of this aspect, the phage
morphogenesis process within the biological system
chosen for peptide display should be considered.
Phage morphogenesis can be divided into three
distinct steps: infection of the host cell, translation
and assembly of the phage particles, and release to
the extracellular environment. Each of these steps
has the potential to impose amino acid sequence bias
on a phage-displayed peptide library (Rodi and
Makowski, 1999). Filamentous phages initiate the
infection process by an interaction between pIII at
the tip of the phage particle and E. coli F pili,
assemble through a complex inner-membrane asso-
ciated process involving bacterial and phage proteins
and are then secreted through the host outer mem-
brane (Fig. 3a) (Russel et al., 2004). On the other
hand, lytic phages initiate infection through an
interaction between their tail ﬁbers and lipopolysac-
charide on the E. coli cell surface, after which the
phage genome and several proteins are injected into
the host cell through its tail (Kemp et al., 2005). Lytic
phage assembly occurs within the E. coli cytoplasm,
and mature phage virions are released by cell lysis
(Fig. 3b). For more information regarding phage
morphogenesis, the reader is referred to the following
Fig. 1. Aﬃnity selection (biopanning) process employed in phage-displayed peptide library screenings. The naı¨ve peptide library is incubated
with the target, washed to remove non-speciﬁc binding phage, and eluted to collect binding phage. The eluted phage are then ampliﬁed in vivo
and subjected to additional rounds of biopanning, or can be plated to isolate clones for sequencing.
* http://www.novagen.com
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and Lowman, 2004).
Because peptides displayed on lytic phage do
not have to be compatible with the host cell
synthesis and secretion apparatuses, libraries pro-
duced with lytic phage can surpass the diversity of
ﬁlamentous phage-displayed peptide libraries. A
recent bioinformatics-assisted comparison of T7
lytic phage and M13 ﬁlamentous phage-displayed
peptide libraries in our laboratory demonstrated
that peptide libraries produced with the T7 system
have less amino acid biases than libraries
produced with the M13 system (Table I). The
overall peptide diversity estimate for a T7 12-mer
random library (T7 12-mer NNK) demonstrated a
14-fold increase over the peptide diversity estimate
for an M13 12-mer random library (M13 12-mer
NNK). For this comparison, the T7 and M13 li-
braries analyzed were constructed using the re-
duced genetic code method of library
oligonucleotide DNA design, or ‘NNK’ method
(see below for further discussion).
Fig. 2. (a) Structure of a typical ﬁlamentous phage virion, and (b) a T7 lytic phage virion.
Fig. 3. Diﬀering processes of ﬁlamentous phage and lytic phage morphogenesis. (a) Filamentous phage assembles at the E. coli inner-
membrane (IM) and is secreted through the outer-membrane (OM) into the extracellular environment, a process that preserves host viability.
(b) Lytic phage assembles within the E. coli cytoplasm, and mature virions are released by cell lysis.
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Peptide Library Increase Diversity
Another factor contributing to the diversity of a
phage-displayed peptide library is the method of li-
brary construction. When designing peptide-encoding
oligonucleotide DNA to be inserted into the phage
genome, the type of genetic code employed is of
utmost importance because the observed frequency of
amino acids displayed in the library is directly cor-
related to the number of codons encoding each amino
acid. For instance, the standard 64-codon genetic
code encodes each of the twenty amino acids and
three stop codons with the number of codons per
amino acid ranging from one (methionine, trypto-
phan) to six (leucine, serine, arginine). Amino acids
encoded by higher numbers of codons have a greater
chance of being incorporated into the library, while
amino acids with fewer codons have a lesser chance.
This discrepancy results in non-uniform amino acid
frequencies and thus, limited peptide diversity.
Ideally, a library would contain peptides with
even 5% amino acid frequencies (one amino acid out
of twenty) per each amino acid position within the
peptides. To produce libraries with more even amino
acid frequencies, phage-displayed peptide libraries
are typically created using a reduced genetic code
when designing the insert oligonucleotide DNA
encoding the displayed peptides. The oligonucleotides
are designed in the ‘NNK’ format, where N repre-
sents equal proportions of guanine, cytosine,
thymine, and adenine nucleotides, and K represents
equal proportions of thymine and guanine nucleo-
tides. This method encodes all twenty amino acids
and one stop codon, while smoothing the number of
codons per amino acid to one, two, or three (Scott,
2001). Although the NNK method of library
construction provides each amino acid a more equal
opportunity of incorporation into the peptide library,
the method still imparts some amino acid sequence
bias because the amino acids are encoded by varying
numbers codons.
An alternative method of library construction
that alleviates the biases imposed by randomized
oligonucleotide DNA methods involves using codon-
corrected trinucleotide cassettes. In this method,
codons for each amino acid are ﬁrst synthesized as
individual trimer nucleotide cassettes, which are then
mixed in appropriate ratios according to the codon
reaction eﬃciencies to form the peptide-encoding
DNA to be inserted into the phage genome. This
method oﬀers several advantages over the random-
ized nucleotide method of library construction.
Undesired stop codons are eliminated from insert
DNA, and because each amino acid is encoded by
only one codon, the method allows for a predeﬁned
ratio of amino acids to be incorporated at each syn-
thesis step. This method is also advantageous in that
it allows the user to deﬁne which amino acid codons
to use based on E. coli codon usage. Previous
research indicates that atypical amino acid codon
usage stresses the host translation system (Kayushin
et al., 1996; Rodi and Makowski, 1999), which may
result in the loss of peptides containing amino acids
encoded by rare codons, and thus limit overall
peptide diversity. Recent research in our laboratory
has shown that a random 12-mer peptide library
constructed with the T7 lytic phage system in com-
bination with the trinucleotide cassettes (Kayushin
et al., 1996) resulted in increased peptide diversity, as
compared to libraries constructed with M13 ﬁla-
mentous phage system and the NNK method
(Table I). The analysis revealed a 3-fold increase in
peptide diversity when using trinucleotide cassettes
(T7 12-mer tri-nucleotide) as compared to the NNK
method (T7 12-mer NNK), and a 43-fold increase in
peptide diversity when using T7 lytic phage and
trinucleotide cassettes, as compared to using M13
ﬁlamentous phage and the NNK method (M13
12-mer NNK).
Tumor-Targeting Peptides Isolated from
Phage-Displayed Peptide Libraries
Within the last several years, there were a number
of articles describing tumor-targeting peptides
isolated from phage-displayed peptide library
screenings. In these research papers, ﬁlamentous
phage-display systems, such as M13 phage, were used







T7 12-mer Tri-nucleotide 0.93 0.419
T7 12-mer NNK 0.85 0.142
M13 12-mer NNK 0.68 0.010
Collections of random peptides isolated from each library were
subjected to analysis by the amino acid sequence diversity (DI-
VAA) program available at http://relic.bio.anl.gov (Rodi et al.,
2004). Diversity per position was calculated by summing the
diversity estimates at each amino acid position of the peptides, and
dividing by 12. Diversity per 12-mer was estimated by raising the
diversity per position to an exponent equal to the length of the
peptide (12).
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lytic phage-displayed systems, such as T7 phage.
Approximately 50% of these articles used linear
peptide libraries, and constrained peptide libraries
were used in the other half of the publications. With
regard to the formats of targets used in biopanning,
about 40% of these articles used recombinantly
expressed proteins that were over-expressed or spe-
ciﬁcally expressed in and on tumor cells. Tumor cell
lines and freshly excised tumor cells were used as
targets in 50% of these research articles without
knowing the exact identity of the target molecules on
tumor cells. The last 10% of these publications used
in vivo and/or ex vivo biopanning methods. All these
research publications showed that speciﬁcity of the
isolated phage clones and/or corresponding peptides
bound to the target molecules in enzyme-linked
immunosorbent assay formats as well as to target
cells in immunoblotting, immunoprecipitation, cell-
binding assays, ﬂow cytometric analyses or immu-
nostaining of cells and tissues. Many of the isolated
peptides, which bound to the targets, were internal-
ized into the cells. However, most studies did not
evaluate the targeting eﬃciency and speciﬁcity of
isolated peptides in vivo. In this article, we decided to
review only the articles within the last several years in
which peptides isolated from phage-displayed peptide
libraries were evaluated in vivo. The reader is referred
to the recent review articles covering the subject
(Aina et al., 2002; Romanov, 2003; Mori, 2004).
Screening Against Recombinant Tumor-Associated
Proteins
Screening phage-displayed peptide libraries
against homogenous recombinant tumor-associated
proteins was the most direct and successful method of
identifying peptidic ligands of target molecules.
Portions of recombinant tumor membrane proteins
including functionally folded extracellular domains,
with and without immunoglobulin domains, were
used during library screenings.
By screening a 9-mer random cyclic peptide
ﬁlamentous phage library, the proapoptotic peptide
P15, which targeted casein kinase 2 (CK2) phos-
phorylation site, was isolated (Perea et al., 2004). P15
peptide abrogated CK2 phosphorylation by blocking
the substrate in vitro. P15 fused to a cell-penetrating
peptide derived from the HIV-Tat protein (P15-Tat)
induced apoptosis by rapid caspase activation and
cellular cytotoxicity in a variety of tumor cell lines. In
addition, in vivo administration of P15-Tat into
C57BL6 mice bearing day 7-established solid tumors
resulted in substantial regression of the tumor mass.
This work suggested that the P15 cyclic peptide might
potentially be used in the treatment of solid tumors.
A novel peptide S7, which selectively bound to
interleukin-6 receptor (IL-6R) chain, was identiﬁed
by screening an M13 phage-displayed 7-mer random
cyclic peptide library (Su et al., 2005). The chemically
synthesized S7 peptide blocked the interaction
between interleukin-6 (IL-6) and interleukin-6
receptor (IL-6R) in a concentration-dependent man-
ner, prevented IL-6-mediated survival signaling, and
sensitized cervical cancer cells to chemotherapeutic
compounds in vitro. It was revealed that the S7
peptide substantially inhibited IL-6-induced vascular
endothelial growth factor-A expression and angio-
genesis in diﬀerent cancer cell lines. In addition, the
authors showed that S7 peptide signiﬁcantly
suppressed IL-6-induced vascular endothelial growth
factor-mediated cervical tumor growth in severe
combined immunodeﬁcient mice. These observations
highlighted the potential use of a small peptide, which
blocks IL-6/IL-6R interaction, in the management of
patients with malignant disease.
Screening Against Whole Cells in Cell Culture
Although peptidic ligands for recombinant tumor
membrane proteins can be identiﬁed using phage-
displayed peptide library technology, the peptides
may not have access to their target in vivo due to
post-translational modiﬁcations and malignancy-
speciﬁc modiﬁcations. In addition, it is often diﬃcult
to recombinantly produce soluble and functionally
folded extracellular domains of membrane proteins.
These issues have prompted many investigators to use
whole intact cells to screen phage-displayed peptide
libraries in vitro. Using this method of biopanning,
speciﬁc peptidic ligands for cell surface molecules and
cell-internalizing peptides were identiﬁed.
An M13 phage-displayed 12-mer random peptide
library was screened to isolate phage that bound
speciﬁcally to human glioma cell lines (Ho et al.,
2004). One of the isolated peptides, MG11, was gli-
oma-speciﬁc and gave an in vitro binding enrichment
of more than 5-fold for glioma cells when compared
with non-glioma cells. Intravenous injection of
phages displaying the MG11 peptide enabled the
phage to target speciﬁcally to glioma xenografts.
Moreover, when Lissamine rhodamine-labeled
MG11 peptide was administered intratumorally, it
targeted speciﬁcally to glioma xenografts.
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dom cyclic peptide library was performed on murine
endothelium under physiological ﬂow conditions to
isolate a family of endothelial vascular adhesion
molecule-1 (VCAM-1)-mediated cell-internalizing
peptides (Kelly et al., 2005). One speciﬁc sequence
(VHSPNKK) having homology to the alpha-chain of
very late antigen (a known ligand for VCAM-1)
bound VCAM-1 and interfered with leukocyte-
endothelial interactions. The peptide showed 12-fold
higher target-to-background ratios as compared with
a VCAM-1 monoclonal antibody. A VHSPNKK-
modiﬁed magnetoﬂuorescent nanoparticle (VNP)
demonstrated high aﬃnity for VCAM-1-expressing
endothelial cells but very low aﬃnity for macro-
phages. VNP targeted VCAM-1-expressing endothe-
lial cells in a murine tumor necrosis factor-induced
inﬂammatory in vivo model and co-localized with
VCAM-1-expressing cells in atherosclerotic lesions
present in cholesterol-fed apolipoprotein E apoE-/-
mice. These results indicated that the VNP could be
useful for in vivo imaging of endothelial markers by
MRI and ﬂuorescence imaging.
A peptide PA1 that internalized to irradiated
Capan-2 pancreatic adenocarcinoma cells was
isolated from an M13 phage-displayed 12-mer ran-
dom linear peptide library (Huang et al., 2005).
Fluorescein-labeled PA1 peptide was able to pene-
trate tumor tissue after intravenous injections to
Capan-2 xenografts in nude mice and bound speciﬁ-
cally to irradiated tumor cells.
An M13 phage-displayed 12-mer random linear
peptide library was screened against the prostate-
speciﬁc membrane antigen-negative cell line DU-145
(Zitzmann et al., 2005). The isolated peptide DUP-1
was evaluated in vitro for its binding speciﬁcity,
kinetics, aﬃnity, and internalization of the peptide.
Biodistribution studies of
131I-labeled DUP-1 in nude
mice with subcutaneously injected DU-145 and PC-3
tumors showed accumulation of the peptide in the
tumors. The rat prostate tumor model AT-1 also
demonstrated an increase of radioactivity in the
prostate tumor up to three-fold in comparison with
normal prostate tissue.
In vivo and Ex vivo Screening
In vivo screening of phage-displayed peptide
libraries involves injecting the library intravenously
into a living host, collecting the tissue of interest,
rescuing the phage clones from that tissue, and sub-
jecting the recovered phage to additional rounds of
selection. After completing several rounds of screen-
ing, the recovered phage clones are analyzed for
binding-motifs. Using this method of phage-
displayed peptide library screening oﬀers advantages
over other methods of selection in that phage are
exposed to the target molecules in their native envi-
ronment. Phage clones displaying peptides that
interact with non-target molecules, such as ubiqui-
tous cell surface proteins and plasma proteins, are
depleted from the phage population. In addition,
only peptides that survive the degradative environ-
ment of the vascular system and only those that can
access their targets are selected and propagated
(Kolonin et al., 2001). The identiﬁcation of peptides
that target selective vasculature through in vivo
phage-displayed peptide library screenings was ﬁrst
reported by Pasqualini and Ruoslahti (1996) and has
since been reviewed (Raﬁi et al., 2003; Zurita et al.,
2003; Mori, 2004; Ruoslahti, 2004).
In 2002, the ﬁrst in vivo screening of a phage-
displayed peptide library in a human patient was re-
ported (Arap et al., 2002b). After one round of
screening, phage that homed to diﬀerent organs were
isolated, and it was found that peptide binding to
these diﬀerent cell types did not occur by a random
process. To validate tissue speciﬁcity of a peptide, the
group demonstrated that an isolated phage displaying
the peptide interacted with the interleukin-11 recep-
tor (IL-11R) present in prostate tissue. IL-11R was
further validated as a candidate for molecularly tar-
geted prostate cancer therapeutics (Zurita et al.,
2004). After demonstrating minimal toxicity of the
in vivo screening of phage-displayed peptide libraries
in mice, another group received Food and Drug
Administration approval for the use of the technique
in human clinical trials (Krag et al., 2002).
As the result of an in vivo screening of ﬁlamen-
tous phage-displayed random peptide libraries, pep-
tides that speciﬁcally recognized the vasculature in
the prostate were identiﬁed (Arap et al., 2002a). One
of the phage clones displaying the peptide SMSIARL
homed to the prostate 10–15 times more than to other
organs, as well as bound to vasculature in the human
prostate. Synthetic SMSIARL peptide inhibited the
prostate-homing of SMSIARL-bearing phage when
co-injected into mice. Systemic treatment of mice
with the peptide linked to a proapoptotic peptide that
disrupts mitochondrial membranes caused tissue
destruction in the prostate. The development of the
cancers in prostate cancer-prone transgenic mice
(TRAMP mice) was also delayed by the chimeric
peptide.
86 Krumpe and MoriA cyclic peptide CPGPEGAGC that homes to
normal breast tissue with a 100-fold selectivity over
non-targeted phage was isolated after in vivo
biopanning of a T7 phage-displayed 7-mer random
cyclic peptide library (Essler and Ruoslahti, 2002).
The CPGPEGAGC-bearing phage binds to the blood
vessels in the breast, as well as the vasculature of
hyperplastic and malignant lesions in transgenic
breast cancer bearing mice. The authors also identi-
ﬁed that the homing peptide bound to aminopepti-
dase P, which is widely expressed in malignant breast
tissue.
Laakkonen et al. (2002) devised a phage screen-
ing procedure that would favor tumor-homing
to targets that are accessible to circulating phage,
but not blood vessels, by combining the ex vivo and
in vivo screening procedures. For the ex vivo screening
portion, tumor-cell suspensions were prepared from
human MDA-MB-435 breast carcinoma xenograft
tumors using collagenase to disperse the tissue. A T7
phage-displayed 7-mer random cyclic peptide library
was ﬁrst incubated with the cell suspension. The
authors then used magnetic beads coated with anti-
mouse CD31 to preferentially deplete the tumor-de-
rived cell suspension of blood vessel endothelial cells.
The ex vivo pre-selected phage pool that bound to the
CD31-deﬁcient cell population was then subjected to
in vivo biopanning on MDA-MB-435 breast carci-
noma xenografts. One of the peptide sequences
enriched was CGNKRTRGC named LyP-1. The
LyP-1-displaying phage bound to primary MDA-
MB-435 tumor-derived cell suspensions about 7000
times more than non-recombinant phage. The ﬂuo-
rescein-labeled LyP-1 synthetic peptide was detected
in tumor structures that were positive for three
lymphatic endothelial markers and negative for three
blood vessel markers and that were accumulated in
the nuclei of the putative lymphatic cells and tumor
cells. LyP-1 peptide also homed to an osteosarcoma
xenograft and spontaneous prostate and breast
cancers in transgenic mice.
Another group screened out novel peptides
homing to angiogenic vessels formed by a dorsal air
sac method from a ﬁlamentous phage-displayed
random 15-mer linear peptide library (Oku et al.,
2002). After the determination of the epitope se-
quences of some of the isolated peptides, a liposome
was modiﬁed with the epitope penta-peptide APRPG.
The liposome demonstrated high accumulation in
murine tumor xenografts, and APRPG-modiﬁed
liposome encapsulating adriamycin eﬀectively sup-
pressed experimental tumor growth. In addition,
speciﬁc binding of APRPG-modiﬁed liposome to
human umbilical endothelial cells was shown.
To identify homing peptides for blood vessels in a
mouse model of HPV16-induced epidermal carcino-
genesis, Hoﬀman et al. (2003) used a T7 phage-
displayed 7-mer random cyclic peptide library for
ex vivo/in vivo biopanning. One peptide, CSRPRR-
SEC, recognized the neovasculature in dysplastic skin
but not in carcinomas. Two other peptides (CGKRK
and CDTRL) preferentially targeted to neovasculature
in tumors and to premalignant dysplasias to a lesser
degree.Thesepeptidesdidnothometovesselsinnormal
skin, other normal organs, or the stages of pancreatic
islet carcinogenesis in another mouse model.
In a combination of ex vivo and in vivo biopan-
ning with a T7 phage-displayed random 7-mer cyclic
peptide library, Joyce et al. (2003) proﬁled the
vasculature in the angiogenic stages of a mouse model
of pancreatic islet carcinogenesis. Seven homing
peptides to angiogenic progenitors, solid tumors, or
both were characterized. Five of them selectively
targeted to neoplastic lesions in the pancreas and not
to islet cell tumors growing subcutaneously,
xenotransplant tumors from a human cancer cell line,
or an endogenously arising squamous cell tumor of
the skin. Three peptides with unique homing to
angiogenic islets, tumors, or both co-localized with
markers of endothelial cells or pericytes. One peptide
was homologous with pro-PDGF-B expressed in
endothelial cells.
In vivo biopanning with laser pressure catapult
microdissection was utilized to screen for peptide
bound vascular receptors in the islets of Langerhans
in the murine pancreas from a ﬁlamentous phage-
displayed 7-mer random cyclic peptide library (Yao
et al., 2005). Two of the isolated peptides showed
sequence identity to ephrin A-type ligand homo-
logues. Confocal microscopy veriﬁed that most
immunoreactivity of the phages displaying these two
peptides was linked with blood vessels in pancreatic
islets. Binding of both islet-homing phage and
antibodies recognizing EphA4, a receptor for
ephrin-A ligands, was dramatically escalated in
blood vessels of pancreatic islet tumors in RIP-Tag2
transgenic mice, indicating that endothelial cells of
blood vessels in pancreatic islets preferentially ex-
press EphA4 receptors, and this expression is
increased in tumors.
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FROM PHAGE-DISPLAYED PEPTIDE
LIBRARIES
Peptides isolated from phage-displayed libraries
can be used as targeting molecules for many appli-
cations: peptides themselves, radiolabeled peptides,
peptides conjugated with chemotherapeutic agents,
peptides fused with toxins, and peptides on nano-
particles or liposomes carrying chemotherapeutic
agents.
Antitumor Activity
Fluorescein-conjugated LyP-1, a peptide selected
from a phage-displayed peptide library that speciﬁ-
cally binds to tumor and endothelial cells of tumor
lymphatics in certain tumors, strongly and speciﬁ-
cally accumulated in primary MDA-MB-435 breast
cancer xenografts and their metastases from intrave-
nous peptide injections (Laakkonen et al., 2004). The
LyP-1 peptide accumulation and hypoxic areas in
tumors overlapped. Systemic LyP-1 peptide admin-
istration of mice with breast cancer xenograft inhib-
ited tumor growth and reduced the number of tumor
lymphatic vessels. The authors suggested that this
unexpected anti-tumor eﬀect by the LyP-1 peptide
could be a starting point for the new anti-tumor agent
targeting to speciﬁc tumor lymphatics.
Drug Delivery
All peptides speciﬁc to tumor and tumor vascu-
lature conjugated with toxic molecules could be
potentially used as therapeutic agents against tumors.
In 1998, Ruoslahti’s group reported that peptides
isolated from in vivo biopanning of phage-displayed
peptide libraries speciﬁcally homed to tumor blood
vessels (Arap et al., 1998). One motif RGD that
selectively bound to avb3 and avb5 integrins, and
another motif NGR that selectively homed to tumor
vasculature. The receptor for the NGR containing
peptides was later identiﬁed as aminopeptidase N
(Pasqualini et al., 2000). These peptides coupled with
the anticancer drug doxorubicin enhanced the
eﬃcacy of doxorubicin against human breast cancer
xenografts in nude mice and reduced its toxicity.
Pasqualini and colleagues conjugated the peptide
containing the RGD or NGR with a programmed
cell death-inducing peptide sequence, KLAK-
LAKKLAKLAK. The homing domains guided the
entire peptides to targeted cells, and the pro-apop-
totic domain disrupted mitochondrial membranes
after internalization of the peptide. These peptides
composed of two functional domains were selectively
toxic to angiogenic endothelial cells and demon-
strated anti-cancer activity in mice (Ellerby et al.,
1999).
Nanomaterial Delivery
Over the last few years, the development of
nanostructures that detect and monitor cancer
markers in vivo and that target therapeutic and
imaging agents to cancer lesions and their microen-
vironment has attracted broad interest in medical
research (Sullivan and Ferrari, 2004; Ferrari, 2005).
Several homing peptides originally isolated from
in vivo screening of phage-displayed peptide libraries
were used for in vivo targeting of semiconductor
quantum dots (qdots) to speciﬁc vascular sites in mice
(Akerman et al., 2002). The qdots coated with a
GFE-1 lung-targeting peptide accumulated in the
lungs of mice after intravenous injection. Two other
peptides named F3 and LyP-1 speciﬁcally targeted
the qdots to blood vessels or lymphatic vessels in
tumors. The authors also show that addition of
polyethylene glycol to the qdot coating reduced
non-selective accumulation of the qdots in reticulo-
endothelial tissues.
Kontermann’s group screened out novel high-
aﬃnity cyclic RGD peptides from phage-displayed
RGD motif libraries against both endothelial and
melanoma cells (Holig et al., 2004). Using one of the
high-aﬃnity peptides RGD10, the authors generated
novel lipopeptides composed of a lipid anchor, a
short ﬂexible spacer, and the peptide ligand conju-
gated to the spacer end. Incorporation of RGD10
lipopeptides into liposomes caused speciﬁc and
eﬃcient binding of the liposomes to integrin-
expressing cells. Furthermore, in vivo experiments
applying doxorubicin-loaded RGD10 liposomes in a
C26 colon carcinoma mouse model demonstrated
improved eﬃcacy.
Imaging
Matrix metalloproteinases (MMPs) play an
important role in cancer as well as in numerous other
diseases. The cyclic decapeptide containing HWGF
that was originally selected from a phage-displayed
peptide library against MMP-2 and MMP-9 was
radiolabed to evaluate the ability of this labeled
peptide to monitor MMP-2 and MMP-9 activity,
88 Krumpe and Moribiodistribution, competition studies and plasma
metabolites analyses in Lewis Lung cancer tumor
bearing mice (Kuhnast et al., 2004). However, the
radiolabeled peptide was not a suitable tracer for
targeting of MMP-2 and MMP-9 in vivo because of
its poor solubility and metabolic instability. Further
modiﬁcation of this peptide is necessary to improve
metabolic stability and hydrophilicity for further
evaluation of this peptide in vivo as a marker of
gelatinase activity.
Gene Targeting
As a gene-targeting molecule, a peptide contain-
ing the NGR motif was inserted into the capsid of
adeno-associated virus vectors. These recombinant
viruses showed an altered tropism toward cells
expressing the CD13 receptor, to which the NGR
motif binds (Grifman et al., 2001). A similar study
using the NGR motif was reported (Liu et al., 2000).
The authors incorporated the NGR motif containing
peptide into the envelope protein of Moloney murine
leukemia virus, and the engineered viruses eﬃciently
transduced human endothelial cells.
PERSPECTIVES
Many target-binding peptides isolated through
the screening of phage-displayed random peptide
libraries modulate the biological function of target
molecules. Therefore, it is possible that certain tumor
and tumor vasculature-targeting bioactive peptides
can directly serve as agonist or antagonists. However,
in general, peptides directly isolated form phage-
displayed random peptides bind to their targets with
low aﬃnity (micromolar range). Thus, it would be
necessary to increase the aﬃnity of the peptides. One
way to improve aﬃnity is to screen second-generation
peptide libraries displayed on phage based on core
motifs identiﬁed from random peptide libraries
(Deshayes et al., 2002; Fleming et al., 2005). Using
this method, it is possible to increase the binding
aﬃnity of target-interacting peptides to the nanom-
olar range (100–1000-fold lower than that of ﬁrst-
generation peptides).
One major bottleneck of all biological display
systems, including phage-displayed combinatorial
peptide libraries, is the use of only the 20 natural
L-amino acids that are prone to degradation by pro-
teases. Thus, selected peptides are susceptible to
proteolytic degradation in vivo unless (1) their amino
and carboxyl termini are protected, (2) they are cyc-
lized, and/or (3) they contain D-amino acids (Aina
et al., 2002). However, it is now possible to geneti-
cally encode unnatural amino acids with diverse
physical, chemical, or biological properties in E. coli,
yeast, and mammalian cells (Xie and Schultz, 2005).
In 2004, Schultz’s group ﬁrst reported a phage
display system with unnatural amino acids (Tian
et al., 2004). This could allow not only the increase of
the complexity of phage-displayed peptide libraries,
but also the enhancement of the proteolytic stability
of peptides isolated from phage display systems.
The other method to desensitize proteolytic
degradation of peptides identiﬁed through phage-
displayed peptide libraries is the mirror-image phage
display approach (Wiesehan and Willbold, 2003).
This technique was used by Kim’s group to identify
D-peptides that bind to the SH3 domain of c-Src
(Schumacher et al., 1996) as well as the coiled-coil
pocket of HIV-1 gp41 (Eckert et al., 1999). Recently,
Wiesehan et al. isolated D-amino-acid peptides that
bind to Alzheimer’s disease amyloid peptide A1-42 by
the mirror-image phage display approach (Wiesehan
et al., 2003). Only a few examples of this application
were reported perhaps because it is expensive to
synthesize D-peptides, and the size of a given target
molecule should be small due to limitation of syn-
thetically available peptide length.
Lam et al. (1991) ﬁrst reported the ‘‘one-bead,
one-compound’’ combinatorial libraries, which may
contain L-amino acids, D-amino acids, unnatural
amino acids, and even non-peptidic moieties. His
group has applied the ‘‘one-bead, one-compound’’
combinatorial library method to successfully dis-
cover peptide ligands for a number of diﬀerent
human cancer cell lines (Aina et al., 2002). Perhaps,
the combination of the phage-displayed peptide li-
brary technique and the ‘‘one-bead, one-compound’’
combinatorial library method should be explored to
identify peptides with high aﬃnity and resistance to
proteolysis. A limitation of the ‘‘one-bead, one-
compound’’ combinatorial library is the realistic
size of the library (up to millions of compounds). It
may be a good idea to screen phage-displayed
random peptide libraries to identify target-binding
motifs at ﬁrst and subsequently screen second-gen-
eration ‘‘one-bead, one compound’’ combinatorial
libraries in which the target-binding motifs are
incorporated. This idea may facilitate the discovery
and development of peptide/peptidomimetics that
are directly useful as diagnostic and therapeutic
agents.
Tumor-Targeting Peptides from Phage-Displayed Libraries 89All the peptides originally isolated from phage-
displayed random peptide libraries could be used as
leads for the rational design of peptidomimetic
compounds (Kay et al., 1998; Nixon, 2002). The
information obtained from structure-activity rela-
tionships and the conformational properties of pep-
tide structures will permit us to develop chemicals
that are protease-resistant, that readily cross the
plasma membrane, and have desirable pharmacoki-
netic properties (Eichler et al., 1995). A number of
examples now exist in which simple peptides have
been converted into peptidomimetics (Kieber-
Emmons et al., 1997; Adessi et al., 2002; Patch and
Barron, 2002).
There also some advantages of peptides over
small molecules since peptide interactions with pro-
tein targets can be more speciﬁc as compared with
small molecules. Large-scale synthesis of peptides has
been dramatically improved (Bray, 2003). Not only
endogenous peptides and their analogs but also
exogenous peptides and their analogs are on the
market. These contribute to the understanding of the
behavior of peptides in serum. Over the last several
years, applications of phage-displayed random pep-
tide library technologies to cancer research led to
many important discoveries. Improvements in library
construction and availability of a variety of phage
display formats will further increase the reliability of
the techniques. In the near future, peptides originally
isolated from phage-displayed random peptide li-
braries could be used as therapeutics and diagnostics
for cancer. We envision that this ﬁeld will draw more
attention in the next few years since the limitation of
antibody-based targeting approach has been realized.
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